Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression.
Yee PP, Wei Y, Kim SY, Lu T, Chih SY, Lawson C, Tang M, Liu Z, Anderson B, Thamburaj K, Young MM, Aregawi DG, Glantz MJ, Zacharia BE, Specht CS, Wang HG, Li W. · 2020
Read Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. by Yee PP, Wei Y, Kim SY, Lu T, Chih SY, Lawson C, Tang M, Liu Z, Anderson B, Thamburaj K, Young MM, Aregawi DG, Glantz MJ, Zacharia BE, Specht CS, Wang HG, Li W. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7591536.txt.
Introduction
Yee and co-authors show that neutrophils drive ferroptosis in glioblastoma tumor necrosis. Dead tissue in tumors predicts poor outcomes for patients. Its cause was thought to be chronic low blood flow.
In a mouse model, neutrophils matched necrosis in time and place. Removing neutrophils reduced necrosis in the tumors. Neutrophils from brain tumors killed cultured tumor cells. They passed myeloperoxidase granules into those tumor cells. That transfer caused iron-linked fat peroxide buildup inside. Blocking myeloperoxidase cut the killing effect sharply. Human tumor data linked neutrophils and ferroptosis to necrosis. They also linked both to poorer patient survival.
Catalog record
| CREATOR | Yee PP, Wei Y, Kim SY, Lu T, Chih SY, Lawson C, Tang M, Liu Z, Anderson B, Thamburaj K, Young MM, Aregawi DG, Glantz MJ, Zacharia BE, Specht CS, Wang HG, Li W. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 129 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression By Patricia P. Yee, Yiju Wei, Soo-Yeon Kim, Tong Lu, Stephen Y. Chih, Cynthia Lawson, Miaolu Tang, Zhijun Liu, Benjamin Anderson, Krishnamoorthy Thamburaj, Megan M. Young, Dawit G. Aregawi Published in: Nature Communications DOI: 10.1038/s41467-020-19193-y ABSTRACT Tumor necrosis commonly exists and predicts poor prognoses in many cancers. Although it is thought to result from chronic ischemia, the underlying nature and mechanisms driving the involved cell death remain obscure. Here, we show that necrosis in glioblastoma (GBM) involves neutrophil-triggered ferroptosis. In a hyperactivated transcriptional coactivator with PDZ-binding motif-driven GBM mouse model, neutrophils coincide with necrosis temporally and spatially. Neutrophil depletion dampens necrosis. Neutrophils isolated from mouse brain tumors kill cocultured tumor cells. Mechanistically, neutrophils induce iron-dependent accumulation of lipid peroxides within tumor cells by transferring myeloperoxidase-containing granules into tumor cells. Inhibition or depletion of myeloperoxidase suppresses neutrophil-induced tumor cell cytotoxicity. Intratumoral glutathione peroxidase 4 overexpression or acyl-CoA synthetase long chain family member 4 depletion diminishes necrosis and aggressiveness of tumors. Furthermore, analyses of human GBMs support that neutrophils and ferroptosis are associated with necrosis and predict poor survival. Thus, our study identifies ferroptosis as the underlying nature of necrosis in GBMs and reveals a pro-tumorigenic role of ferroptosis. Together, we propose that certain tumor damage(s) occurring during early tumor progression (i.e. ischemia) recruits neutrophils to the site of tissue damage and thereby results in a positive feedback loop, amplifying GBM necrosis development to its fullest extent. INTRODUCTION Tumor necrosis is a histopathological term used to generally describe tissue death in cancers. It is a common feature and poor prognostic predictor in a variety of advanced cancers, such as invasive breast cancer1, non-small cell lung cancer2, malignant mesothelioma3, clear cell renal cell carcinoma4, malignant gastrointestinal stromal tumors5, Ewing’s sarcoma of the bone6, endometrial cancer7, and glioblastomas (GBMs)8. Necrosis in GBM, the deadliest and most common primary adult brain malignancy, is of particular interest since it is a diagnostic hallmark and positively correlates with tumor aggressiveness and poor outcomes8–10. Like other solid tumors, GBMs are characterized by extensive tissue hypoxia, likely due to rapid tumor expansion outstripping vascular supply11. It is thought that hypoxia serves as the initial trigger of necrosis, instigating cell death by precluding oxidative phosphorylation and abruptly depleting intracellular ATP. Although ATP depletion may disrupt a series of intracellular homeostatic processes and lead to uncontrolled cell death, the nature of tumor necrosis remains ill-defined, and the molecular mechanisms underlying its development remain unclear. Damaged tissues, described histologically as necrosis, are immunogenic. They release damage-associated molecular patterns (DAMPs), such as high-mobility group protein B1 (HMGB1). DAMPs often act as chemoattractants to recruit neutrophils, the most abundant immune cell in human blood, to the site of necrosis12. Although traditionally considered a homogeneous and short-lived population, it is now appreciated that neutrophils exhibit heterogeneous immunophenotypes with dynamic functional plasticity. Beyond their ties to tissue damage, neutrophils are well-known to be present in various types of cancers as so-called tumor-associated neutrophils (TANs). Their strong correlation with a variety of advanced cancers has attracted a long-standing interest in exploring neutrophils as clinical biomarkers and therapeutic targets. However, the roles of neutrophils in cancer remain controversial13–15. On one hand, recent studies suggested that neutrophils can promote tumor progression by releasing factors to promote remodeling of the extracellular matrix, stimulate angiogenesis, and modulate other inflammatory cells. Factors released by neutrophils can also directly promote tumor cell proliferation and invasion. On the other hand, neutrophils can also play anti-tumor roles by virtue of their cytotoxicity. Studies of neutrophil-triggered cytotoxicity under different contexts suggested that neutrophil-derived reactive oxygen species (ROS), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), or hydrogen peroxide is responsible for neutrophil-mediated tumor cell-killing16,17. Nevertheless, the mechanisms by which the killing is accomplished, the type of cell death, and the implications for tumor progression remain elusive. Ferroptosis is a type of iron-dependent regulated cell death mediated by lethal accumulation of lipid peroxides18. Disruption of glutathione-dependent lipid peroxide reduction systems leads to the accumulation of lipid-based ROS. This can be triggered by disrupting the function of the system Xc− cystine/glutamate antiporter or glutathione peroxidase 4 (GPX4)19. Because of cancer cells’ high iron levels and their increased sensitivity to ferroptosis induction, ferroptosis has been proposed to be promising for cancer therapeutics20. Consistent with this notion, expression of tumor suppressors, such as p53 or BAP1, in cancer cells can inhibit tumorigenesis by inducing ferroptosis21,22. However, p53 expression can also inhibit ferroptosis in some cancer cells23,24, suggesting the role of ferroptosis in cancer could be complex and deserves further investigation. In this study, we investigate the roles of neutrophils in GBM tumor necrosis using an orthotopic xenograft GBM mouse model faithfully recapitulating the extent of necrosis observed in GBM patients. This model exhibits the temporal and spatial correlation between necrosis and neutrophils. We demonstrate that neutrophil depletion reduces GBM necrosis and that TANs isolated from GBM tumor-bearing mice, as well as granulocyte colony-stimulating factor (G-CSF) activated mature neutrophils induce tumor cell death when cocultured in vitro. Mechanistically, such neutrophil-mediated tumor cell killing is achieved via ferroptosis and relies on intercellular transfer of neutrophil-specific granules into tumor cells. The granules contain myeloperoxidase (MPO), whose activity is required for the tumor cell killing. Suppressing ferroptosis by manipulating key ferroptosis regulators in tumor cells, such as GPX4 and acyl-CoA synthetase long chain family member 4 (ACSL4), reduces necrosis and dampens tumor aggressiveness. Finally, we provide evidence that neutrophils and ferroptosis are also associated with tumor necrosis and poor survival in GBM patients. RESULTS Hyperactivating TAZ promotes GBM mesenchymal (MES) transition and tumor necrosis Transcriptional coactivator with PDZ-binding motif (TAZ) is an oncogenic transcriptional regulator in the Hippo pathway. It was shown that the TAZ-driven transcriptional program is associated with GBM MES differentiation and aggressive progression25. To examine if TAZ expression is increased in the MES subtype of GBM, we analyzed the TCGA GBM dataset through cBioPortal (www.cbioportal.org). More tumors of MES subtype show higher TAZ expression than those of proneural (PN) or classical (CL) subtypes (Fig. 1a). To study how TAZ activation drives aggressive GBM progression, we devised a TAZ-driven xenograft GBM mouse model by stably expressing a constitutively active TAZ mutant (TAZ4SA)26 in a commonly used LN229 human GBM cell line (Supplementary Fig. 1a), which contains a P98L missense mutation in p53 (Cancer Cell Line Encyclopedia). Mice intracranially implanted with TAZ4SA-expressing tumor cells (hereafter denoted LN229TAZ(4SA)) showed significantly shorter survival than those implanted with vector-transduced tumor cells (hereafter denoted LN229vector) (Fig. 1b). LN229TAZ(4SA) tumors grow much faster than LN229vector tumors (Supplementary Fig. 1b). These results were consistent with previous observations27 and suggested that the former tumors are more aggressive than the latter ones. Blotting the tumor lysates for MES markers (fibronectin, CD44, and CTGF) revealed that LN229TAZ(4SA) tumors express these proteins at higher levels, suggesting a MES transformation in vivo (Fig. 1c). Histological studies found that LN229TAZ(4SA) tumors are much more heterogeneous than LN229vector tumors and contain large areas of necrosis, whereas LN229vector tumors do not develop detectable necrosis (Fig. 1d–f). Notably, such a difference existed even when LN229TAZ(4SA) and LN229vector tumors were examined at the same size (Supplementary Fig. 1c), suggesting that tumor size does not determine the presence or absence of tumor necrosis. Since